enzastaurin

01/01/2023 - "Several clinical trials observed that enzastaurin prolonged QT interval in cancer patients. "
04/05/2016 - "The pharmacokinetics of enzastaurin in Chinese cancer patients were consistent with those observed in previous studies abroad. "
01/01/2016 - "Rather than undertake a formal thorough QT study, the effect of enzastaurin on the QT was assessed by combining the QT corrected for heart rate (QTc) intervals from 3 clinical pharmacology studies totaling 85 patients with cancer receiving multiple therapeutic or supratherapeutic doses of enzastaurin. "
01/01/2016 - "Preclinical and interim results from a clinical pharmacology study in patients with cancer indicated that enzastaurin might have the potential to prolong the QT. "
10/01/2010 - "Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors."

12/01/2018 - "Phase II studies regarding PKC-β inhibitor, enzastaurin, showed promising results in MCL, DLBCL and recurrent high-grade gliomas. "
09/08/2008 - "The initial objective of this study was to assess the efficacy of enzastaurin in a series of malignant human glioma cell lines with diverse genomic alterations. "
02/01/2010 - "A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas."
05/15/2009 - "Enzastaurin has activity in a subset of malignant glioma patients and warrants continued study in combination with other agents using a maximal once daily dose of 500 mg."
05/15/2009 - "A phase I trial of enzastaurin in patients with recurrent gliomas."

05/01/2020 - "Enzastaurin as a potent inhibitor of PKC-β and PI3K/AKT pathway suppressor has been tested in many clinical trials including two key studies in DLBCL: Phase III maintenance study (Preventing Relapse in Lymphoma Using Daily Enzastaurin [PRELUDE]) and a first-line Phase II study (S028). "
08/01/2013 - "A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas."
06/01/2006 - "Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. "
04/05/2016 - "This study was conducted to assess the pharmacokinetics and safety of enzastaurin in native Chinese patients with refractory solid tumors and lymphoma. "
04/05/2016 - "A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma."

10/01/2012 - "A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer."
07/01/2010 - "A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer."
07/01/2010 - "Both schedules of enzastaurin in combination with pemetrexed were well tolerated and clinically active in patients with advanced non-small cell lung cancer."
03/01/2010 - "The combination regimen of enzastaurin and pemetrexed is well tolerated but does not improve efficacy over pemetrexed and placebo as second-line treatment of unselected patients with advanced non-small cell lung cancer."
01/01/2010 - "Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC)."

01/01/2016 - "A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma."
11/01/2007 - "A recent phase II study of enzastaurin in patients with relapsed or refractory diffuse large B-cell lymphoma showed enzastaurin to be associated with prolonged freedom from progression. "
01/01/2016 - "Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma."
05/01/2007 - "Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma."
05/01/2010 - "Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. "